Drug Database
ER

erythropoietin beta (CinnaPoietin ß / CinnaPoietin)

✓ Approved

Cinnagen Co · EPOR · Recombinant Proteins

What is erythropoietin beta?

erythropoietin beta is a recombinant proteins developed by Cinnagen Co. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or subcutaneous injection.

Drug Profile

Brand NamesCinnaPoietin ß, CinnaPoietin
CompanyCinnagen Co
Drug ClassRecombinant Proteins
Molecular TargetEPOR
RouteInjectable (Others), Intravenous (IV), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Cinnagen Co

Mechanism of Action

Molecular Targets

erythropoietin beta acts on 1 molecular target:

EPORerythropoietin receptor (EPO-R)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

erythropoietin beta is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Blood and lymphatic system disordersAnaemia✓ Approved
Blood and lymphatic system disordersNephrogenic anaemia✓ Approved

Related Research Articles

PubMedInternational journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists2026-07-25

SOX2 Can Support a Diagnosis of PiMHEC With Rare to Absent Ghost Cells and Can Distinguish PiMHEC From Its Most Problematic Mimickers.

Xu Jin J, Weisman Paul S PS

Pilomatrix-like high-grade endometrioid carcinoma (PiMHEC) is an aggressive variant of endometrioid adenocarcinoma characterized by divergent pilomatrical differentiation. While classic cases are usually recognizable, the diagnosis can be challenging when ghost cells are rare or absent, or when encountering mimickers that share overlapping features. We investigated the utility of SOX2 immunohistochemistry as a diagnostic marker for PiMHEC. SOX2 expression was evaluated in 26 cases of PiMHEC (24 endometrial, 2 ovarian). We also analyzed problematic mimickers, including non-PiMHEC FIGO grade 3 endometrioid carcinomas (EMCA) with aberrant beta-catenin expression (n=4) and undifferentiated/dedifferentiated EMCA (UD-EMCA) with aberrant beta-catenin expression (n=7). In addition, a tissue microarray (TMA) of 84 EMCA cases (FIGO grade 1-3 and UD-EMCA) was screened. All 26 PiMHEC cases (100%) showed robust SOX2 positivity. In contrast, all non-PiMHEC FIGO grade 3 EMCAs with aberrant beta-catenin expression were negative for SOX2. While 2 of 7 UD-EMCAs with aberrant beta-catenin expression showed very focal SOX2 expression, these were easily distinguished from PiMHEC by their lack of cytokeratin expression. In the TMA cohort, only 5 of 84 cases (all FIGO grade 3) showed SOX2 positivity; these cases all had membranous beta-catenin expression, had no histologic features of PiMHEC and followed an indolent clinical course. SOX2 is a useful marker for confirming a diagnosis of PiMHEC, especially when ghost cells are inconspicuous. It effectively differentiates PiMHEC from its FIGO grade 3 mimickers with aberrant beta-catenin expression.

PMID 42498260
Read full article →
PubMedRevista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia2026-07-25

Effectiveness of single-dose methotrexate in the treatment of ectopic pregnancy: a retrospective study.

Mendonça Letícia Pereira LP, da Fonseca Eduardo Cunha EC

Evaluate the effectiveness of Methotrexate in clinical treatment of ectopic pregnancy and analyze the influence of clinical and laboratory variables on the treatment outcome. It was a retrospective study of 95 patients undergoing clinical treatment with Methotrexate at a private tertiary hospital in the metropolitan region of Belo Horizonte. Variables such as age, presence of pelvic pain, previous ectopic pregnancy, initial beta-hCG level and largest adnexal mass measurement were analyzed. The theoretical framework followed a data search in PubMed, selecting 17 articles in total. The clinical success rate with a dose of Methotrexate was 71,6%. Among the variables evaluated, only the initial beta-hCG value showed statistical significance with the outcome, therefore, higher the beta-hCG, lower the chance of treatment effectiveness, with a p-value of 0.002. The other variables analyzed did not show any significant association. Methotrexate has been shown to be effective in most cases of ectopic pregnancy, with the initial beta-hCG value standing out as a predictor of treatment failure. The findings reinforce the importance of adequate patient selection and laboratory monitoring in clinical follow-up.

PMID 42500184
Read full article →
PubMedMedicine2026-07-25

Survival benefit of concurrent beta-blocker use in cancer patients treated with radiotherapy: A systematic review and meta-analysis.

Xu Wentong W, Xin Yong Y, Yang Xue X, Wu Mengyang M et al.

Both preclinical and retrospective studies have implicated β-adrenergic signaling in cancer progression, leading to interest in β-blockers (BBs) as adjunctive anticancer agents. There is evidence that they may enhance the sensitivity of cancer cells to radiotherapy and other conventional therapies. We conducted a systematic review and meta-analysis to explore the radiosensitizing effects of BBs. PubMed, the Cochrane Library, Embase, Web of Science, the China National Knowledge Infrastructure, the China biology medicine database, Wan fang Data, and the VIP database were searched for articles in both English and Chinese from the establishment of the databases to September 8, 2025, to identify studies comparing outcomes according to beta-blocker use (yes vs no) in patients with solid tumors treated with radiotherapy. The primary endpoint was overall Survival (OS), Secondary objectives included 1, 2, 5-Year Survival, disease-free survival, distant metastasis-free survival, locoregional progression-free survival and progression-free survival (PFS). 8 studies (3165 patients), including 7 retrospective cohort studies and 1 randomized controlled trial, were analyzed. The most common cancer was non-small cell lung cancer (n = 5). BB use was associated with significantly improved OS (hazard ratio [HR] 0.73, 95% confidence interval: 0.64-0.83). Benefits were also observed for disease-free survival (HR 0.69) and Distant Metastasis-Free Survival (HR 0.62), indicating reduced recurrence and metastasis. In this meta-analysis, the use of BBs during or around radiotherapy may be associated with longer OS in cancer patients, suggesting that it may enhance the efficacy of radiotherapy and provide a survival benefit. Alternatively, the effect of β-blockers on survival may shift from a nonspecific effect to an intriguing cancer-specific effect over time. Beta-blockers are an intriguing option to explore in prospective studies of patients with solid tumors undergoing radiotherapy.

PMID 42499029
Read full article →
PubMedRadiology case reports2026-07-25

Beta-ketothiolase deficiency with progressive basal ganglia and extra basal ganglia involvement: CT-MRI correlation in a pediatric metabolic encephalopathy: A case report.

Gebre Berihu B, Gereziher Yirgalem Y, Gebrewahd Dejen D, Alcober Catherine C

Beta-ketothiolase deficiency (BKTD), also called mitochondrial acetoacetyl-CoA thiolase (T2) deficiency, is a rare autosomal recessive inborn error of metabolism affecting isoleucine catabolism and ketone body utilization. Although recurrent ketoacidotic crises are the hallmark of the disease, neurological complications-particularly basal ganglia injury-are increasingly recognized. We report a 2-year-old girl with known BKTD who presented with severe euglycemic ketoacidosis and acute encephalopathy. Initial CT showed symmetric hypodensity confined to the bilateral globus pallidi. Follow-up CT during ongoing metabolic instability demonstrated interval progression to involve the bilateral putamina and cerebral peduncles. MRI, obtained after referral, revealed nonenhancing T2/FLAIR hyperintense, T1 hypointense globus pallidus lesions without diffusion restriction but with punctate SWI hypointensities consistent with microcystic cavitary degeneration and microhemorrhage. There were additional diffusion-restricting lesions in the bilateral cerebral peduncles, small nonrestricting white matter foci in the frontal and right parietal lobes, and generalized cerebral atrophy. A baseline MRI 17 months earlier had been normal. This case illustrates the evolution from acute pallidal injury to irreversible basal ganglia necrosis with microhemorrhage and concurrent acute/subacute tract involvement, and highlights how CT and MRI together can characterize the spectrum of BKTD-related brain injury.

PMID 42500497
Read full article →
PubMedAnnals of pediatric cardiology2026-07-25

Trans-2,3-enoyl-CoA reductase-like-related catecholaminergic polymorphic ventricular tachycardia in a child: Clinical course and management outcomes.

Kulbachinskaya E K EK, Pushkov A A AA, Bereznitskaya V V VV, Zhanin I S IS et al.

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare but potentially fatal inherited arrhythmia. We report a 7-year-old child with CPVT associated with a homozygous trans-2,3-enoyl-CoA reductase-like c.730 + 1G>C variant. To our knowledge, this variant has not been previously reported in the indexed peer-reviewed literature. Prophylactic implantation of an implantable cardioverter defibrillator before symptom onset proved lifesaving during a subsequent ventricular fibrillation episode despite beta-blocker therapy.

PMID 42499835
Read full article →
PubMedMedicine2026-07-25

Assessing the causal influence of biomechanical factors on osteoporosis risk: A multivariable Mendelian randomization investigation.

Dai Yong-Jun YJ, Xiao Xian-Pei XP, Li Hong-Xu HX, Mao Jun-Jie JJ et al.

While observational studies indicate correlations between multiple biomechanical traits and osteoporosis, causal inference has been constrained, impeding the clinical application of these measures in risk stratification. This Mendelian randomization (MR) study examines causal associations of ankle spacing width (ASW), height, body mass index (BMI), grip strength, and usual walking pace with bone mineral density (BMD) across skeletal sites and age groups. Genetic proxies for the exposures were derived from the Medical Research Council Integrative Epidemiology Unit and UK Biobank resources. Genetic association estimates for the outcomes were acquired from the Genetic Factors for Osteoporosis Consortium. Two-sample and multivariable MR analyses were applied to infer causality. Genetically proxied ASW (encompassing left, right, and combined measures) and height showed an inverse association with estimated BMD (eBMD; Beta < 0, P. adjusted < .05). In contrast, genetically predicted BMI was associated with an increase in eBMD (Beta > 0, P. adjusted < .05). Moreover, genetically predicted ASW was linked to lower total body BMD, with the inverse association being most pronounced in the 0 to 15 years age group. Multivariable MR analyses confirmed that ASW remained independently associated with both eBMD and total body BMD after adjusting for confounding factors. Our findings offer genetic evidence indicative of a causal detrimental effect of ASW and height on BMD, especially during early life stages, whereas BMI demonstrates a potentially protective causal role.

PMID 42499092
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about erythropoietin beta